Cue Biopharma develops injectable treatments that target specific immune cells for autoimmune and inflammatory diseases. CUE reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 18 | B. Riley Securities | Initiated | Buy |
Seasonality
How CUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in CUE in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CUE is in one of them and how their past CUE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CUE in an article yet. Here's the latest on the wider market.
About Cue Biopharma
Cue Biopharma is a biopharmaceutical company based in Somerville, Massachusetts, that is developing injectable treatments for autoimmune and inflammatory diseases. Its drug candidates are designed to act on specific immune cells, aiming to calm harmful immune responses while leaving the rest of the immune system largely intact. Its lead program is still in preclinical work, and some of its other candidates have been licensed to outside drugmakers. The company's target patients are people living with these conditions.
- Headquarters
- Somerville, MA